



PharmaMar and Boryung Pharm sign a licensing agreement for Zepsyre® (lurbinectedin) in Korea

Madrid, November 7th, 2017 – PharmaMar (MSE:PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre® (lurbinectedin), if approved, in South Korea. Under the terms of the agreement, PharmaMar receives a non-disclosed upfront payment and will be eligible for additional remunerations upon achieving regulatory and sales milestones. PharmaMar will retain exclusive production rights and will sell the product to Boryung Pharm for commercial use, if approved.

Zepsyre® is currently in late-stage clinical development for platinum-resistant ovarian cancer and for small-cell lung cancer. After results obtained in clinical trials about BRCA 2-associated metastatic breast cancer and endometrial cancer, PharmaMar also plans to initiate a pivotal phase III study in each of those indications.

According to Luis Mora, Managing Director of PharmaMar's Oncology Business Unit, *"this is our second strategic agreement with Boryung Pharm and we are very pleased with our business partner. This new agreement will allow Zepsyre® to reach the Korean market, if approved, in the hands of one of the leading companies in the field of oncology in this country"*.

Boryung Pharm Chief Executive Officer, Mr. Tae-Hong Choi said, *"we are very pleased to have our second licensing deal with PharmaMar. This licensing deal will strengthen our existing strong relationship with PharmaMar and demonstrate our high confidence in PharmaMar's development pipeline."* He added: *"Zepsyre® may provide new therapies in various types of solid tumors, including a platinum-resistant ovarian cancer, BRCA 2-associated metastatic breast cancer and small-cell lung cancer. We look forward to making these new therapies available in South Korea, if approved."*

About Zepsyre® (lurbinectedin)

Zepsyre® is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction. The antitumor efficacy of lurbinectedin is being investigated in various types of solid tumors, including a Phase III study for platinum-resistant ovarian cancer, a Phase II study for BRCA 1 and BRCA 2-associated metastatic breast cancer and a Phase III study for small cell lung cancer.

About Boryung Pharmaceutical Co., Ltd.,

Established in 1963, Boryung Pharmaceutical has been one of Korea`s leading pharmaceutical companies with sales revenue of KRW 400 billion, 1,155 employees and 550 sales representatives as of 2015. The company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea. The company has focused on the development and commercialization of new pharmaceutical products. Its main therapeutic categories are oncology, cardiovascular, anti-infective, respiratory and others. Especially Boryung is the strongest company in anti-cancer market in Korea. Additional information can be found at www.boryung.co.kr

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, lurbinectedin, plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000

**Investor Relations:**

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

###